Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Department of Hematology, Shigatse Municipal People's Hospital, Shigatse, 857000, Tibet, China.
Target Oncol. 2021 Jan;16(1):13-26. doi: 10.1007/s11523-020-00763-5.
The prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in patients with cancer has been inconsistent across previous studies.
This meta-analysis aimed to investigate the prognostic significance of sPD-L1 in human tumors.
A comprehensive search of PubMed, Web of Science, Embase, and Cochrane databases from inception to January 6, 2020 was conducted. Studies of sPD-L1 measured by enzyme-linked immunosorbent assay (ELISA) that had available hazard ratios (HRs) for survival outcomes based on high or low sPD-L1 levels were included. The primary endpoint was long-term survival, namely, overall survival (OS), and the second endpoint was short-term survival, including progression-free survival (PFS), disease-free survival (DFS), recurrence-free survival (RFS), and cancer-specific survival (CSS).
A total of 21 studies, with 2413 patients, were included in this meta-analysis. Elevated sPD-L1 was associated with worse OS [HR = 2.46, 95% confidence interval (CI) 1.74-3.49, P < 0.001]. Moreover, high sPD-L1 was predictive of worse PFS/DFS/RFS/CSS (HR = 2.22, 95% CI 1.47-3.35, P < 0.001). High sPD-L1 was consistently correlated with poor OS and PFS/DFS/RFS/CSS irrespective of study design, sample, and cut-off value of sPD-L1. However, there was non-significant correlation between sPD-L1 and sex, age, clinical stage, Eastern Cooperative Oncology Group Performance Status, tumor differentiation, or serum lactate dehydrogenase.
This meta-analysis showed that sPD-L1 was correlated with poor prognosis in human tumors. In addition, sPD-L1 could be used as a predictive factor of inferior outcomes during multiple malignancy treatments.
可溶性程序性死亡配体 1（sPD-L1）在癌症患者中的预后价值在以往的研究中不一致。
本荟萃分析旨在研究 sPD-L1 在人类肿瘤中的预后意义。
从建库到 2020 年 1 月 6 日，对 PubMed、Web of Science、Embase 和 Cochrane 数据库进行了全面检索。纳入了通过酶联免疫吸附试验（ELISA）测量 sPD-L1 且具有基于 sPD-L1 高水平的生存结局危险比（HR）的研究。主要终点为长期生存，即总生存期（OS），次要终点为短期生存，包括无进展生存期（PFS）、无病生存期（DFS）、无复发生存期（RFS）和癌症特异性生存期（CSS）。
本荟萃分析共纳入 21 项研究，共 2413 例患者。sPD-L1 升高与 OS 较差相关[HR = 2.46，95%置信区间（CI）1.74-3.49，P < 0.001]。此外，sPD-L1 水平高与 PFS/DFS/RFS/CSS 较差相关（HR = 2.22，95%CI 1.47-3.35，P < 0.001）。无论研究设计、样本量和 sPD-L1 截断值如何，sPD-L1 与 OS 和 PFS/DFS/RFS/CSS 较差均呈一致性相关。然而，sPD-L1 与性别、年龄、临床分期、东部肿瘤协作组体能状态、肿瘤分化或血清乳酸脱氢酶无显著相关性。
本荟萃分析表明，sPD-L1 与人类肿瘤的不良预后相关。此外，sPD-L1 可作为多种恶性肿瘤治疗中预后不良的预测因子。
